Newsroom
Sorted by: Latest
-
Riassunto: NIQ torna a IFA 2026 per guidare le conversazioni di settore su crescita, innovazione IA e trasformazione dei consumatori
BERLINO--(BUSINESS WIRE)--In qualità di Official Global Insights Partner di IFA Berlin 2026, NIQ (NYSE: NIQ) continuerà a rivestire un ruolo fondamentale nella definizione delle discussioni di settore, raccogliendo dati, intelligence basata sull'IA e strategia umana per gettare luce sulle forze che stanno plasmando crescita, innovazione e comportamento dei consumatori. Tramite interventi dei dirigenti, tavole rotonde, analisi di mercato esclusive e iniziative strategiche con i clienti (tra cui...
-
NIQ revient à l’IFA 2026 pour animer les débats du secteur sur la croissance, l’innovation, l’IA et la transformation des habitudes de consommation
BERLIN--(BUSINESS WIRE)--En tant que partenaire officiel Global Insights de l’IFA Berlin 2026, NIQ (NYSE : NIQ) continuera à jouer un rôle de premier plan dans l’orientation des débats du secteur, en combinant données, intelligence artificielle et expertise humaine pour mettre en lumière les forces qui redéfinissent la croissance, l’innovation et le comportement des consommateurs. Grâce à des discours d’ouverture prononcés par des dirigeants, des tables rondes, des informations exclusives sur l...
-
NIQ kehrt zur IFA 2026 zurück, um den Branchendialog zu den Themen Wachstum, Innovation, KI und Wandel im Verbraucherverhalten anzuführen
BERLIN--(BUSINESS WIRE)--Als offizieller Global Insights Partner der IFA Berlin 2026 wird NIQ (NYSE: NIQ) weiterhin eine führende Rolle bei der Gestaltung von Branchendiskussionen spielen und Daten, KI-gestützte Erkenntnisse sowie menschliche Einsichten zusammenführen, um die Kräfte zu beleuchten, die Wachstum, Innovation und Verbraucherverhalten neu gestalten. Durch Keynotes von Führungskräften, Podiumsdiskussionen, exklusive Marktinformationen und strategische Kundenkontakte (einschließlich d...
-
Samenvatting: NIQ keert terug naar IFA 2026 om sectorgesprekken over groei, innovatie, AI en transformatie van de consument te leiden
BERLIJN--(BUSINESS WIRE)--Als de Official Global Insights Partner van IFA Berlin 2026 zal NIQ (NYSE: NIQ) een leidende rol blijven spelen in de vormgeving van sectorbesprekingen, waarbij data, informatie aangestuurd door AI en menselijk inzicht worden samengebracht om de krachten te belichten die groei, innovatie en consumentengedrag hervormen. Aan de hand van toespraken van executives, panelbesprekingen, exclusieve marktinformatie en strategische klantengagementen (waaronder deelname aan de IF...
-
NIQ重返IFA 2026,引领关于增长、创新、AI与消费者转型的行业对话
柏林--(BUSINESS WIRE)--(美国商业资讯)-- 作为IFA Berlin 2026的官方全球洞察合作伙伴,NIQ (NYSE: NIQ)将继续发挥主导作用,塑造行业讨论,将数据、AI驱动的智能与人类洞察相结合,揭示重塑增长、创新和消费者行为的核心力量。通过高管主旨演讲、小组讨论、独家市场情报以及战略性客户互动(包括参加IFA零售领袖峰会、第四届NIQ商业早餐会以及一场专为中小企业打造的专属活动),NIQ将帮助全球科技生态系统将快速的市场变化转化为可执行的商业机遇。 围绕今年IFA的主题“未来即当下”(The Future Is Now),NIQ将就重塑消费科技、家用电器和零售业的力量提供及时的行业视角——涵盖AI驱动的创新、不断演变的消费者期望、全渠道转型以及新兴的增长机遇。 在品牌和零售商应对经济不确定性、购买行为转变以及日益增强的价格敏感度之际,NIQ的最新市场数据凸显了该行业面临的挑战与机遇。尽管部分地区的科技和耐用消费品市场仍面临压力,但欧洲主要市场的增长仍在持续,这进一步凸显了创新、敏捷性以及数据驱动决策的重要性。 NIQ全球科技与耐用消费品高级副总裁Perr...
-
NIQ重返IFA 2026,引領關於成長、創新、AI與消費者轉型的產業對話
柏林--(BUSINESS WIRE)--(美國商業資訊)-- IFA Berlin 2026的官方全球洞察合作夥伴NIQ (NYSE: NIQ)將繼續發揮主導作用,塑造產業討論,將資料、AI驅動的智慧與人類洞察相結合,揭示重塑成長、創新和消費者行為的核心力量。透過高階主管主題演講、小組討論、獨家市場情報以及策略性客戶互動(包括參加IFA零售領袖高峰會、第四屆NIQ商業早餐會以及一場專為中小企業打造的專屬活動),NIQ將協助全球科技生態系統將快速的市場變化轉化為可執行的商機。 圍繞今年IFA的主題「未來即當下」(The Future Is Now),NIQ將就重塑消費科技、家用電器和零售業的力量提供及時的產業視角——涵蓋AI驅動的創新、不斷演變的消費者期望、全通路轉型以及新興的成長機會。 在品牌和零售商因應經濟不確定性、購買行為改變以及日益強化的價格敏感度之際,NIQ的最新市場資料彰顯了該產業面臨的挑戰與機會。儘管部分地區的科技和耐用消費品市場仍面臨壓力,但歐洲主要市場的成長仍在持續,這進一步彰顯了創新、敏捷性以及資料驅動決策的重要性。 NIQ全球科技與耐用消費品資深副總裁Perry...
-
Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic
NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a collaboration and co-exclusive licensing agreement with AstraZeneca. Under this agreement, the companies will advance AZD4241, a preclinical investigational therapy for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, with Pathos assuming responsibility for the early clinical devel...
-
Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC
NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly-owned subsidiary of Alphamab Oncology (Stock Code: 9966.HK), on JSKN016, a first-in-class (FIC) TROP2/HER3 bispecific antibody-drug conjugate (ADC) independently developed by Alphamab. Pursuant to the licensing agreement, Alphamab granted Pathos an exclusive...
-
INVESTOR ALERT: Securities Class Action Filed Against Wise Group plc – Investors Encouraged to Contact Kirby McInerney LLP
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Wise Group plc (“Wise” or the “Company”) (NASDAQ: WSE) common stock between May 11, 2026 and July 23, 2026, inclusive (“the Class Period”).If you suffered a loss on your Wise investments, you have until September 29, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. If yo...
-
INVESTOR ALERT: Securities Class Action Filed Against Capricor Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) common stock between December 17, 2025 and July 26, 2026, inclusive (“the Class Period”).If you suffered a loss on your Capricor investments, you have until September 28, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted...